Delay in recognition of pulmonary arterial hypertension: Factors identified from the REVEAL registry

Chest

Volumn 140, Issue 1, 2011, Pages 19-26

  Brown, Lynette M ^a,b   Chen, Hubert ^c   Halpern, Scott ^d   Taichman, Darren ^d   McGoon, Michael D ^e   Farber, Harrison W ^f   Frost, Adaani E ^g   Liou, Theodore G ^b   Turner, Michelle ^h   Feldkircher, Kathy ⁱ   Miller, Dave P ^h   Elliott, C Gregory ^a,b  

^a INTERMOUNTAIN MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e MAYO CLINIC   (United States)

^f BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h ICON CLINICAL RESEARCH   (United States)

ⁱ Actelion Pharmaceuticals US Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DELAYED DIAGNOSIS; DISEASE DURATION; DISEASE REGISTRY; DISEASE SEVERITY; ETHNIC DIFFERENCE; FEMALE; GEOGRAPHIC DISTRIBUTION; HEART ATRIUM PRESSURE; HEART CATHETERIZATION; HEMODYNAMICS; HUMAN; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OBSTRUCTIVE AIRWAY DISEASE; ONSET AGE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RACE DIFFERENCE; SEX DIFFERENCE; SLEEP APNEA SYNDROME; SYMPTOM; UNITED STATES; WALKING;

EID: 79960103454     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-1166     Document Type: Article

References (30)

1. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(suppl 1):S43-S54.
2. McGoon MD, Torbicki A, Oudiz RJ. Diagnosis and Assessment of Pulmonary Arterial Hypertension. West Sussex, England: John Wiley and Sons, Ltd; 2008.
3. Voelkel NF, Quaife RA, Leinwand LA, et al; National Heart, Lung, and Blood Institute Working Group on Cellular and Molecular Mechanisms of Right Heart Failure. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation. 2006;114(17):1883-1891. (Pubitemid 44673364)
4. Tueller C, Stricker H, Soccal P, et al; Swiss Society for Pulmonary Hypertension. Epidemiology of pulmonary hypertension: new data from the Swiss registry. Swiss Med Wkly. 2008;138(25-26):379-384. (Pubitemid 351969707)
5. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023-1030.
6. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107(2):216-223. (Pubitemid 17137857)
7. Jing ZC, Xu XQ, Han ZY, et al. Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest. 2007;132(2):373-379.
8. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106(12):1477-1482.
9. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780-788. (Pubitemid 34925627)
10. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137(2):376-387.
11. Galiè N, Ghofrani HA, Torbicki A, et al; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148-2157.
12. Galiè N, Olschewski H, Oudiz RJ, et al; Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008; 117( 23): 3010-3019.
13. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896-903. (Pubitemid 34984638)
14. Barst RJ, Rubin LJ, Long WA, et al; The Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296-302.
15. Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006;28(6):1195-1203. (Pubitemid 44883856)
16. Chang AM, Mumma B, Sease KL, Robey JL, Shofer FS, Hollander JE. Gender bias in cardiovascular testing persists after adjustment for presenting characteristics and cardiac risk. Acad Emerg Med. 2007;14(7):599-605. (Pubitemid 46920980)
17. Bond M, Bowling A, McKee D, et al. Does ageism affect the management of ischaemic heart disease? J Health Serv Res Policy. 2003;8(1):40-47. (Pubitemid 36083150)
18. Mehta RH, Bufalino VJ, Pan W, et al; American Heart Association Get With the Guidelines Investigators. Achieving rapid reperfusion with primary percutaneous coronary intervention remains a challenge: insights from American Heart Association's Get With the Guidelines program. Am Heart J. 2008;155(6):1059-1067.
19. Gorin SS, Heck JE, Cheng B, Smith SJ. Delays in breast cancer diagnosis and treatment by racial/ethnic group. Arch Intern Med. 2006;166(20):2244-2252. (Pubitemid 44748771)
20. McGoon MD, Krichman A, Farber HW, et al. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc. 2008;83(8):923-931.
21. Gold PM. The 2007 GOLD guidelines: a comprehensive care framework. Respir Care. 2009;54(8):1040-1049.
22. Rich S, Levy PS. Characteristics of surviving and non-surviving patients with primary pulmonary hypertension. Am J Med. 1984;76(4):573-578. (Pubitemid 14127545)
23. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343-349.
24. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 suppl):S55-S66.
25. McLaughlin VV, Archer SL, Badesch DB, et al; American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians;American Thoracic Society, Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53(17):1573-1619.
26. Ayanian JZ, Weissman JS, Schneider EC, Ginsburg JA, Zaslavsky AM. Unmet health needs of uninsured adults in the United States. JAMA. 2000;284(16):2061-2069.
27. Martin S, Ulrich C, Munsell M, Taylor S, Lange G, Bleyer A. Delays in cancer diagnosis in underinsured young adults and older adolescents. Oncologist. 2007;12(7):816-824. (Pubitemid 47328225)
28. McWilliams JM, Meara E, Zaslavsky AM, Ayanian JZ. Health of previously uninsured adults after acquiring Medicare coverage. JAMA. 2007;298(24):2886- 2894.
29. Hayes D Jr. Idiopathic pulmonary arterial hypertension misdiagnosed as asthma. J Asthma. 2007;44(1):19-22.
30. Valerio CJ, Coghlan JG. Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient. Vasc Health Risk Manag. 2009;5:607-619.